In another swift, early-to-market move,Bristol-Myers Squibb Co.’s Opdivo has become the first checkpoint immunotherapy to secure FDA approval in kidney cancer.
The agency approved Bristol’s PD-1 inhibitor Opdivo (nivolumab) on Nov. 23 for advanced renal cell carcinoma, after prior treatment with...